Science and Enterprise

Category: Joint ventures/collaborations

  • Compound That Repairs RNA Defects Identified

    Researchers at Scripps Research Institute in Jupiter, Florida have identified a compound that can help repair defects in ribonucleic acid (RNA), a genetic material similar to DNA used in protein synthesis. The team’s findings appear online in the journal ACS Chemical Biology (paid subscription required). The researchers, led by Scripps chemistry professor Matthew Disney (pictured…

  • University, Company Partner to Combat Counterfeit Chips

    The College of Nanoscale Science and Engineering (CNSE) of the University at Albany and Applied DNA Sciences Inc. in Stony Brook, New York will collaborate on nanotechnology-based solutions to prevent counterfeiting of computer chips. The partnership will focus on new methods for depositing DNA on nanoelectronics wafers and computer chips for authentication. This collaboration in…

  • UC San Francisco, Sanofi to Partner on Diabetes Therapies

    University of California in San Francisco (UCSF) and the French pharmaceutical company Sanofi have agreed to collaborate on diabetes research. Under the $3.1 million partnership, UCSF and Sanofi will share their expertise and identify new drug targets for type 1 and type 2 diabetes. The collaboration is expected to bring together researchers in UCSF labs…

  • Sanofi, VCs Back Start-Up Deriving Natural Product Drugs

    The French drug maker Sanofi, with American venture capital (VC) companies Third Rock Ventures and Greylock Partners, are investing up to $125 million in Warp Drive Bio a new biotechnology company in Cambridge, Massachusetts. Warp Drive Bio, being incubated at Third Rock Ventures, specializes in using genomics to derive drug candidates from natural sources, such…

  • Foundation to Fund Drug Maker Diabetic Eye Disease Research

    KalVista Pharmaceuticals in Southampton, U.K. and JDRF in New York have formed a partnership to develop a drug candidate with potential to slow the advance of diabetic macular edema (DME). The collaboration aims to move KalVista’s plasma kallikrein inhibitor into human proof-of-concept clinical trials and generate clinical data to highlight its potential as a new…

  • Electronics Show to Feature Science Start-Up Exhibits

    The 2012 CES in Las Vegas, the world’s largest consumer electronics trade show, will feature an exhibit of start-up companies and technologies emerging from research and development, including small businesses funded by National Science Foundation. The exhibit, called Eureka Park, is a collaboration of the National Science Foundation (NSF), Startup America Partnership, CNET, and UK…

  • Forma, Boehringer Ingelheim to Partner on Cancer Drugs

    Forma Therapeutics, a biotechnology company in Watertown, Massachusetts says it signed an agreement with the German pharmaceutical maker Boehringer Ingelheim to discover and develop drug candidates for cancer. The deal involves the discovery of small molecule drugs targeting interactions among proteins. Forma’s technology for cancer drug discovery involves computational and medicinal chemistry, parallel synthesis, and…

  • Stem Cells to be Produced for Research in Muscle Disorders

    BioTime Inc. in Alameda, California says it will market to researchers progenitors of muscle stem cells bearing hereditary diseases. The company says it will produce the cells from five human embryonic stem cell (hESC) lines provided by Reproductive Genetics Institute (RGI) in Chicago. The cell lines will display the genes for six hereditary muscle diseases:…

  • Emergent BioSolutions, Abbott Labs End Collaboration

    As reported yesterday, Emergent BioSolutions Inc. in Rockville, Maryland has started a phase 2 clinical study of its drug candidate TRU-016, a program conducted in partnership with pharmaceutical manufacturer Abbott Laboratories. Emergent BioSolutions now says that Abbott Laboratories has ended the partnership agreement to develop and commercialize the compound. Daniel J. Abdun-Nabi, president of Emergent…

  • NIH Establishes Medical Translational Science Center

    The federal 2012 fiscal year spending bill passed by Congress and signed by President Obama before Christmas includes approval for National Institutes of Health (NIH) to form a new research center devoted to turning discoveries in the lab into new drugs, diagnostics, and devices. The National Center for Advancing Translational Sciences (NCATS), with a budget…